Keywords: Hikma Pharma, Financial results 2010, MENA turmoil
Hikma delivers strong sales and 25% earnings growth in 2010
Article | 17 March 2011
Jordon-headquartered drugmaker Hikma Pharmaceuticals (LSE: HIK) reported its preliminary results for the year ended December 31, 2010, yesterday, with group revenues up 14.8% ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
